Company / Shareholders' Equity
Pacira BioSciences, Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$693.1M
FY2025
5-year range
$354.9M / $870.1M
FY2021-FY2025
Trend
-11.0%
vs FY2024
Sector context
#66 of 213
Health Care
What the data says
At $693M, Pacira BioSciences, Inc.'s shareholders' equity ranks #66 of 213 in the Health Care sector. Declined from $870M to $693M over the past 2 years.
Based on SEC 10-K filings.
$693M in FY2025 with a 5-year CAGR of +16.6%.
Declined from $870M to $693M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -3.7%
- 5-Year CAGR
- +16.6%
- 10-Year CAGR
- -
Sector benchmark
#66 of 213 in Health CareTop 31% of 213This company $693.1M Sector average $2.5B
▼
-72.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +16.6%, indicating consistent growth.
- In FY2025, shareholders' equity decreased 11.0% year-over-year.
- Ranks #66 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2023.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Negative profit margin: -14.8%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $693.1M | -11.0% |
| FY2024 | $778.3M | -10.5% |
| FY2023 | $870.1M | +12.3% |
| FY2022 | $775.0M | +118.3% |
| FY2021 | $354.9M | +10.5% |
| FY2020 | $321.2M | +14.9% |
| FY2019 | $279.5M | +27.6% |
| FY2018 | $219.0M | +0.3% |
| FY2017 | $218.4M | -0.3% |
| FY2016 | $219.0M | +0.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026